Ostrum Asset Management Biomarin Pharmaceutical Inc Transaction History

Ostrum Asset Management

$1.9 Trillion
Q1 2025

A detailed history of Ostrum Asset Management transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ostrum Asset Management holds 21,322 shares of BMRN stock, worth $1.21 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

21,322

Previous 21,546 1.04%

Holding current value

$1.21 Million

Previous $1.42 Billion 6.43%

% of portfolio

0.08%

Previous 0.12%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$61.25 - $72.83 $13,720 - $16,313	-224 Reduced 1.04%	21,322 $1.51 Billion
Q4 2024 Feb 13, 2025	SELL	$61.93 - $70.49 $749,538 - $853,140	-12,103 Reduced 35.97%	21,546 $1.42 Billion
Q3 2024 Nov 13, 2024	BUY	$69.02 - $93.84 $17,462 - $23,741	253 Added 0.76%	33,649 $2.37 Billion
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $118,790 - $147,183	-1,596 Reduced 4.56%	33,396 $2.75 Billion
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $470,963 - $608,693	-6,179 Reduced 15.01%	34,992 $3.37 Billion
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $181,964 - $202,092	-2,139 Reduced 4.94%	41,171 $3.64 Billion
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $21,670 - $25,075	-250 Reduced 0.57%	43,310 $3.75 Billion
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $2.07 Million - $2.76 Million	23,560 Added 117.8%	43,560 $4.24 Billion
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $610,895 - $1.11 Million	8,500 Added 73.91%	20,000 $1.52 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $914,825 - $1.43 Million	11,500 New	11,500 $1.42 Million

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.6B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ostrum Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Ostrum Asset Management with notifications on news.

Account

Ostrum Asset Management Biomarin Pharmaceutical Inc Transaction History